Research Reports

Key takeaways

Revenue increased 127% to $3.6M from $1.6M in Q1 2025, reflecting higher HEMGENIX sales royalties received from CSL Behring.

Gross profit rose 144% to $3.3M from $1.4M year-over-year, achieving a 93.9% gross margin on elevated royalty revenues.

Operating loss expanded 16% to $45.7M from $39.3M, driven by R&D expenses tied to biopharmaceutical research and development activities.

Net loss grew 23% to $53.5M or $(0.85) diluted EPS from $43.6M or $(0.82) in the prior year.

Operating cash use improved to $38.2M from $44.1M, supported by a $3.3M net decrease in accounts payable, accrued expenses, other liabilities, and operating leases.

Full analysis

uniQure N.V. reported Q1 2026 results reflecting robust top-line momentum from HEMGENIX royalties alongside persistent investment in its gene therapy platform. Revenue accelerated 127.3% year-over-year to $3.6 million from $1.6 million, driven by higher royalty payments from CSL Behring tied to HEMGENIX sales. This fueled gross profit growth of 144.0% to $3.3 million, yielding a high 93.9% gross margin that underscores the favorable economics of our royalty-based revenue model post-manufacturing transfer to Genezen under the commercial supply agreement.

Operationally, the Genezen CSA enables focus on core R&D by outsourcing HEMGENIX manufacturing and supply to meet CSL Behring's commercial demand. Looking forward, certain obligations are expected payable between 2030 and 2034, aligning with long-term pipeline milestones like randomized controlled trials for proof-of-concept data. These dynamics position uniQure to leverage royalty momentum while sustaining innovation, balancing near-term losses against multi-year value creation in gene therapy.

QURE · uniQure N.V.

Summary

Key takeaways

Full analysis